TWST Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
118.4M
+6.9%
110.7M
+6.8%
103.7M
+4.7%
99.0M
+3.1%
96.1M
Cost of Revenue
55.9M
+4.3%
53.6M
+7.8%
49.7M
+3.2%
48.2M
+7.6%
44.8M
Gross Profit
62.5M
+9.3%
57.1M
+5.8%
54.0M
+6.2%
50.8M
-0.9%
51.3M
Operating Expenses
98.7M
-4.1%
103.0M
+18.5%
86.9M
+7.6%
80.8M
-0.8%
81.4M
R&D
18.0M
-8.5%
19.7M
+15.0%
17.1M
+0.7%
17.0M
-5.7%
18.0M
SG&A
80.7M
+6.1%
76.1M
+9.1%
69.7M
+9.4%
63.8M
+0.6%
63.4M
Operating Income
-36280000
+20.9%
-45863000
-39.4%
-32900000
-9.9%
-29934000
+0.6%
-30120000
EBITDA
-29502000
+8.5%
-32244000
-20.7%
-26706000
-11.6%
-23930000
+0.5%
-24055000
Net Income
-35051000
+20.4%
-44021000
-44.3%
-30507000
-12.4%
-27138000
-233.1%
20.4M
EPS (Basic)
$-0.56
+21.1%
$-0.71
-42.0%
$-0.50
-11.1%
$-0.45
-232.4%
$0.34
EPS (Diluted)
$-0.56
+21.1%
$-0.71
-42.0%
$-0.50
-8.7%
$-0.46
-239.4%
$0.33
Shares (Diluted)
62.4M
+1.1%
61.7M
+1.0%
61.1M
+3.1%
59.3M
-3.1%
61.2M
Twist Bioscience (TWST) โ€” Financials